Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 8/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945187 | 1.00 | CA3 (0.44) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL2525720 | 0.82 | CA3 (0.50) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL28161686 | 0.79 | ESR1 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL573864 | 0.78 | MAOB (0.53) | TRPV4MAOAMAOB | |
| SCHEMBL28406222 | 0.77 | CA3 (0.44) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL74807 | 0.76 | TRPV4 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL21116203 | 0.76 | USP8 (0.42) | TRPV4MAOAMAOB | |
| SCHEMBL1267040 | 0.76 | ESR2 (0.44) | CA3CA6CA9CA14XDH | |
| SCHEMBL28843641 | 0.75 | AR (0.41) | CA9ESR2MEN1KMT2A | |
| Bromide SCHEMBL28616522 | 0.74 | ESR2 (0.43) | CA3CA6CA9CA14XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557929-A | Somatostatin modulators and uses thereof | 克林提克斯医药股份有限公司 | 2023-01-03 | — | — | CN | claimed |
| EP-3484865-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | claimed |
| US-11414397-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-08-16 | — | — | US | claimed |
| EP-0103918-A2 | Pesticidal benzoylurea compounds | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-03-28 | — | — | EP | claimed |
| JP-59161349-A | — | — | None | — | — | JP | disclosed |
| JP-59134767-A | — | — | None | — | — | JP | disclosed |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4585598-A1 | MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Suzhou Langrui Biopharmaceutical Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | EMPRESS THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-0152014-B1 | 2-CYANO-4-HALOGENOPHENYL SUBSTITUTED-BENZOATES AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THEM | Chisso Corporation (JP) | 1988-04-20 | — | — | EP | disclosed |
| US-4659501-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1987-04-21 | — | — | US | disclosed |
| US-4603018-A | NEGATIVE DIELECTRIC ANISOTROPIC LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1986-07-29 | — | — | US | disclosed |
| EP-0106588-B1 | 2-CYANO-4-HALOGENOPHENYL ESTERS | Chisso Corporation (JP) | 1986-04-30 | — | — | EP | disclosed |
| EP-0152014-A2 | 2-Cyano-4-halogenophenyl substituted-benzoates and liquid crystal compositions containing them | Chisso Corporation (JP) | 1985-08-21 | — | — | EP | disclosed |
| JP-S59161349-A | LIQUID CRYSTAL COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY | CHISSO CORP | 1984-09-12 | — | — | JP | disclosed |
| JP-S59134767-A | ESTER COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY | CHISSO CORP | 1984-08-02 | — | — | JP | disclosed |
| EP-0106588-A1 | 2-Cyano-4-halogenophenyl esters | Chisso Corporation (JP) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414397-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | CA3 2191/4885CA6 1209/4885CA5A 800/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | CA3 1760/4885CA6 591/4885CA5A 2182/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | CA3 4766/4885CA6 4244/4885CA5A 2980/4885 |
| US-20250197388-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | SI, VIP, APC | CA3 4131/4885CA6 576/4885CA5A 3216/4885 |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE2, WEE1, ROR1 | CA3 3990/4885CA6 3629/4885CA5A 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.